Capacidad antioxidante de péptidos obtenidos de hidrolizados de tilapia con bromelina y papaína.

Se realizaron hidrolizados con restos del fileteado de tilapia utilizando extractos de piña y papaya como fuente de enzimas proteolíticas (bromelina y papaína). Se obtuvieron muestras de los hidrolizados a diferentes tiempos (30 minutos, 1, 24, 48 y 72 horas) eliminando los sólidos por centrifugación. Los péptidos solubles fueron separados mediante precipitación de proteínas con TCA, y la absorbancia a 280 nm del sobrenadante fue utilizada como medida de su concentración. La capacidad antioxidante de los péptidos obtenidos con bromelina y papaína a diferentes tiempos de hidrólisis fue determinada mediante la prueba de ORAC. Los péptidos obtenidos del hidrolizado elaborado a base de cascara de piña mostraron la mayor actividad antioxidante

Cuantificación de antioxidantes en plantas de tomate (Solanum lycopersicon L. Mill) enriquecida con selenio.

Con el propósito de analizar la capacidad del selenito de sodio para incrementar la concentración de Selenio y modificar la actividad antioxidante en plantas de tomate. Se aplicaron tres tratamientos de selenito de sodio utilizando como vehículo el agua de riego. Se llevaron a cabo tres muestreos 40, 80 y 120 días después del tras plante y cuantificaron la acumulación de selenio en frutos. Se obtuvo una cuantificación del potencial oxido reducción y de la actividad de antioxidante como la catalasa, glutatión peroxidasa, el ácido ascórbico y licopeno. Para cada variable se llevó a cabo un análisis de varianza. Los resultados mostraron un incremento en la acumulación de selenio, hasta un 53.1% con el tratamiento 5 mg L-1en comparación con el testigo. Los valores del potencial oxido-reducción se redujeron desde -41.4 mV para el testigo y hasta -68.0 mV con el mayor tratamiento. La concentración de Se influyó en los parámetros de calidad incluyendo el ácido ascórbico hasta un 50% de aumento y el licopeno (66.9%). La actividad de las enzimas antioxidantes aumentó notablemente en el fruto con el tratamiento 5 mg L-1de selenito encontrándose 60.9% de aumento para CAT, 33.4% para GPX y 26.0% para SOD

Calidad nutricional del tomate (Solanum lycopersicon L. Mill) enriquecida con selenio.

La biofortificación tiene como finalidad incrementar la concentración de elementos biodisponibles en cultivos hortalizas para elevar la calidad nutricional. El selenio es un elemento traza de gran impacto para el metabolismo antioxidante de las plantasy su acumulación es pobre en especies como el tomate, por lo que adicionarlo en las plantas forma parte de los programas de biofortificación. El propósito de este trabajo fue analizar la capacidad del selenito de sodio para incrementar la concentración de Se y modificar la actividad antioxidante en plantas de tomate. Para ello a l a s plantas se aplicaron tres tratamientos 0, 2 y 5 mg L-1 de selenito de sodio utilizando como vehículo el agua de riego. Se llevaron a cabo tres muestreos 40, 80 y 120 días después del trasplante y cuantificación la acumulación de selenio y macronutrientes en hojas, tallos y frutos asícomo su impacto en la producción de frutos bajo un diseño experimental completamente al azar. Se determinó la altura, diámetro de tallos, firmeza, sólidos solubles de frutos y la materia seca total de los diferentes tejidos. Se obtuvo una cuantificación del potencial oxido reducción y de la actividad de antioxidante específicos como la catalasa, glutatión peroxidasa, superóxido dismutasa, el ácido ascórbico y licopeno. Los resultados se analizaron mediante el ANOVA y posteriormente una prueba de comparación de medias de Tukey. Se observó un incremento en la acumulación de Se, encontrándose hasta un 53.1% de aumento en la concentración en los frutos bajo el tratamiento 5 mg L-1 en comparación con el testigo, sin embargo, este incremento no tuvo un impacto notorio en la producción y el rendimiento del tomate. La concentración de Se influyó positivamente en los parámetros de calidad incluyendo el ácido ascórbico y el licopeno

Propiedades fisicoquímicas y actividad antioxidante de chiltepín cultivado bajo mallas sombra de colores.

En la última década han surgido en el mercado mallas de colores que debido a sus propiedades fotosintéticas que mejoran el aprovechamiento de la radiación solar en los cultivos protegidos. En este trabajo se evaluó la influencia de mallas sombra sobre las propiedades fisicoquímicas y actividad antioxidante de frutos de chiltepín. Se determinaron las siguientes variables de estudio; pH, Sólidos solubles totales, acidez titulable, color, vitamina “C” y actividad antioxidante por DPPH. El diseño experimental utilizado fue completamente al azar y la prueba de comparaciones de medias de Tukey (p≤ 0.05). No se observaron diferencias significativas en acidez titulable. Se observó una mayor brillantez en los frutos de chiltepín cultivados bajo invernadero, mientras que el mayor valor de a* y Croma se observó en los frutos de chiltepín cultivado bajo malla azul. El mayor contenido de sólidos solubles totales se observó en los frutos cultivados bajo malla roja, y el mayor contenido de vitamina “C”, se observó en los frutos de chiltepín cultivados en campo y bajo malla sombra de color azul, sin embargo la mayor actividad antioxidante se observó en los frutos cultivados en campo y bajo invernadero

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

A Minimal Regulatory Network of Extrinsic and Intrinsic Factors Recovers Observed Patterns of CD4+ T Cell Differentiation and Plasticity

<div><p>CD4+ T cells orchestrate the adaptive immune response in vertebrates. While both experimental and modeling work has been conducted to understand the molecular genetic mechanisms involved in CD4+ T cell responses and fate attainment, the dynamic role of intrinsic (produced by CD4+ T lymphocytes) versus extrinsic (produced by other cells) components remains unclear, and the mechanistic and dynamic understanding of the plastic responses of these cells remains incomplete. In this work, we studied a regulatory network for the core transcription factors involved in CD4+ T cell-fate attainment. We first show that this core is not sufficient to recover common CD4+ T phenotypes. We thus postulate a minimal Boolean regulatory network model derived from a larger and more comprehensive network that is based on experimental data. The minimal network integrates transcriptional regulation, signaling pathways and the micro-environment. This network model recovers reported configurations of most of the characterized cell types (Th0, Th1, Th2, Th17, Tfh, Th9, iTreg, and Foxp3-independent T regulatory cells). This transcriptional-signaling regulatory network is robust and recovers mutant configurations that have been reported experimentally. Additionally, this model recovers many of the plasticity patterns documented for different T CD4+ cell types, as summarized in a cell-fate map. We tested the effects of various micro-environments and transient perturbations on such transitions among CD4+ T cell types. Interestingly, most cell-fate transitions were induced by transient activations, with the opposite behavior associated with transient inhibitions. Finally, we used a novel methodology was used to establish that T-bet, TGF-β and suppressors of cytokine signaling proteins are keys to recovering observed CD4+ T cell plastic responses. In conclusion, the observed CD4+ T cell-types and transition patterns emerge from the feedback between the intrinsic or intracellular regulatory core and the micro-environment. We discuss the broader use of this approach for other plastic systems and possible therapeutic interventions.</p></div